Royalty Report: Drugs, Delivery, Biotechnology – Collection: 26607

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Delivery
  • Biotechnology
  • cardiac
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26607

License Grant
The Licensee desires to obtain, and the University desires to grant an  exclusive, world-wide License under the Licensed Patents to make, have made, use, market and sell Products within the Field of Use; with the right to grant subLicenses.
License Property
Technology, as used in this Agreement, shall mean all information, manufacturing techniques, data, designs or concepts covering (a) the surface modified biodegradable nanoparticles and methods of making and using same, useful in delivering bioactive material into biological systems as described in Michigan’s Technology Management Office File Nos. 800, 800pl, and 938 all entitled Surface Modified Biodegradable Nanoparticles and Methods of Making and Using Same, and File No. 1019 entitled Biodegradable Hydroxy-Terminated Poly (epsilon-caprolactone)  Polyether Multi-Block Biodegradable Co-polymers Useful Drug Carriers for Biologically Active Agents, encompassing U.S. Patent Application Nos. 08/369,541 and 08/389,893 both entitled Surface Modified Biodegradable Nanoparticles and Methods of Making and Using Same; (b) certain genes and means of transferring gene segments into cells of bone and other tissues as described in Michigan’s Technology Management Office File No. 926 entitled Gene Transfer into Bone and Tissues, and File Nos. 926p1, 926p2 and 926p3 all entitled Methods and Compositions for Stimulating Bone Cells, encompassing U.S. Patent Application No. 08/199,780 entitled Gene Transfer into Bone and Tissues, No. 08/316,650 entitled Methods and Compositions for stimulating Bone Cells, and No. PCT/US95/02251 entitled Methods and Compositions for Stimulating Bone Cells, and a U.S. Patent Application filed June 7, 1995 entitled Latent TGFß Binding Protein (LTBP) Genes, Compositions and Methods; and (c) certain genes, gene segments and cDNA clones, all related to the TGFß-superfamily of genes, and a method for the isolation of such genes as described in Michigan’s Technology Management Office File No. 1116.
Field of Use
Field of Use shall mean all fields except (i) the delivery of cyto-skeletal inhibitors for treatment or prevention of cardiovascular disease and cardiovascular trauma; (ii) the use of heparin or dexamethasone for the treatment or prevention of restenosis or other cardiovascular disease or cardiovascular trauma; and (iii) the oral delivery of vaccines.

IPSCIO Record ID: 27353

License Grant
The University hereby grants to Licensee exclusive licenses under Patent Rights to make, use, sell, offer for sale, and import Patent Products in the Field and to practice the Patent Method in the Field; Applications of Coated Nanocrystalline Particles (Invention), useful in the development of vaccine adjuvants, virus vaccine constructs, drug delivery systems, and a red blood cell surrogate.
License Property
U.S. Patent No. 5,178,882 entitled 'Viral Decoy Vaccine, U.S. Patent No. 5,219,577 'Biologically Active Composition Having a Nanocrystalline Core', U.S. Patent No. 5,306,508 entitled 'Red Blood Cell Surrogate', U.S. Patent No. 5,334,394  entitled 'Human Immunodeficiency Virus Decoy'
U.S. Patent No. 5,460,830 entitled 'Biochemically Active Agents for Chemical Catalysis and Cell Receptor Activation', U.S. Patent No. 5,460,831 entitled 'Targeted Transfection Nanoparticles', U.S. Patent No. 5,462,750 entitled 'Biologically Active Compositions Having a Nanocrystalline Core', U.S. Patent No. 5,462,751 entitled 'Biological and Pharmaceutical Agents Having a Nanomeric Biodegradable Core' and U.S. Patent No. 5,464,634 entitled 'Red Blood Cell Surrogate'.
Field of Use
'Field' means vaccine Adjuvant, Virus Vaccine Construct, Drug Delivery System and Red Blood Cell Surrogate.

IPSCIO Record ID: 282943

License Grant
The Netherlands Licensee hereby grants to Licensor, and Licensor hereby accepts, the right of first refusal to be granted a license under all future patents and patent applications in connection with the PolyActive Technology for the non-exclusive use by Licensor of the PolyActive Technology in the Orthopedic Field and/or for use as a medical device not containing a biological active agent(s). Such right will be subject to a royalty.

Licensee grants to Licensor and Licensor accepts, as from the Effective Date, an exclusive, unlimited, world-wide, perpetual, royalty-free license, with the right to grant sub-licenses to make, use, sell, market and develop any PolyActive Rights B relating to osseouschondral and/or osteochondral plugs, fillers, cement restrictors, or the like, including but not limited to SynPlug(TM) (Licensee License B.)

Licensee grants to Licensor and Licensor accepts, as from the Effective Date, an exclusive, unlimited, world-wide, perpetual, royalty-free license, with the right to grant sub-licenses to make, use, sell, market and develop any PolyActive Rights A and/or PolyActive Rights B related to the use of the PolyActive Technology in a medical device to be used to measure and/or monitor blood glucose (Licensor License AB).

License Property
PolyActive Technology shall mean a drug delivery system controlling the release of biologically active molecules, which is based on PolyActive. Products based on PolyActive Technology can be used for both local and systemic administration, and have applications in pharmaceutics and medical technology.

PolyActive shall mean a biodegradable (amphiphilic) poly(ether-ester) multiblock copolymer based on PEGT and PBT.

CHIENNA-Patents shall mean the patents and patent applications defined and listed in Annex I(A) to the ACLA.

PolyActive Rights A shall mean the PolyActive Rights A as defined and listed in Annex 3.2, consisting of the CHIENNA-Patents but not including all previously abandoned and/or transferred patents and patent applications.

6,685,957 – Preparation of fibrous polymer implant containing bioactive agents using wet spinning technique
5,980,948 – Polyetherester copolymers as drug delivery matrices

PolyActive Rights B Shall mean the PolyActive Rights B as defined and listed in Annex 3.1, consisting of the Licensor-Patents but not including (1) all previously abandoned and/or transferred patents and patent applications; (2) the Osteoinduction patent family; and (3) the Cement Restrictor 4th Design.

6,479,418 – Porous ceramic body
6,069,295 – Implant material

Field of Use
PolyActive is a biodegradable polymeric drug delivery system.  Licensee uses PolyActive to develop its controlled-release alfa interferon product LocteronTM.

Locteron is a controlled release formulation of interferon alfa for the treatment of chronic hepatitis C, currently in Phase IIa studies.

Orthopedic Field shall mean that part of the Licensees patents and patent application which relate to a therapeutic application to the musculoskeletal system, including bone, cartilage, joints, related connective tissues, ligaments, tendons and nerves.

PolyActive technology and its intellectual property in certain strategic areas, including additional applications in orthopedics.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.